灸法治疗轻度认知障碍:多中心随机对照研究

Clinical effect and safety of moxibustion therapy in treatment of mild cognitive impairment:a multi-center randomized controlled trial

目的:观察“三才益智”灸法早期干预轻度认知障碍(MCI)的临床疗效及安全性。方法:采用随机数字表法将纳入的210例MCI患者随机分为灸法组和药物组,每组105例。灸法组采用艾灸百会、神阙和涌泉穴,每次20min,隔日1次,共治疗8周;药物组口服尼莫地平30mg/次,1次/d,连续服用8周。两组分别于治疗前、治疗8周后及治疗结束后12周随访时评价各组简易精神状态评价量表(MMSE)评分、临床记忆量表(CMS)无意义图形再认评分和事件相关电位P300潜伏期,分析评价两组治疗的安全性。结果:与治疗前比较,两组患者治疗后及随访时MMSE评分、CMS无意义图形再认评分均明显升高(P<0.01,P<0.05),P300潜伏期明显缩短(P<0.01)。与同时点药物组比较,灸法组治疗后MMSE评分明显升高(P<0.05),治疗后及随访时P300潜伏期明显缩短(P<0.05)。结论:“三才益智”灸法可改善MCI患者认知障碍,是改善MCI患者认知功能的有效干预方式。

Objective To investigate the clinical effect and safety of moxibustion therapy based on Sancai theory for reinforcing intelligence in the early intervention of mild cognitive impairment(MCI).Methods A total of 210patients with MCI were divided into moxibustion group and medication group using a random number table,with 105patients in each group.The patients in the moxibustion group were given moxibustion at Baihui(GV20),Shenque(CV8),and Yongquan(KI1)once every other day,20minutes each time,for a total of 8weeks,and those in the medication group were given oral Nimodipine 30mg once a day for 8weeks.Mini-Mental State Examination(MMSE)score,score of meaningless graphics recognition of Clinical Memory Scale(CMS),and event-related potential P300latency were evaluated before treatment,after 8weeks of treatment,and at 12 weeks after treatment,and the safety of treatment was analyzed for both groups.Results Both groups had significant increases in MMSE score and the score of meaningless graphics recognition of CMS and a significant reduction in P300latency after treatment and during follow-up(P<0.01,P<0.05).Compared with the medication group,the moxibustion group had a significant increase in MMSE score and a significant reduction in P300latency after treatment(P<0.05).Conclusion Moxibustion therapy based on Sancai theory for reinforcing intelligence can improve cognitive impairment in patients with MCI and is thus an effective intervention method for improving the cognitive function of patients with MCI.